日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

HIDEA syndrome: A new case report highlighting similarities with ROHHAD syndrome

HIDEA综合征:一例新病例报告,强调其与ROHHAD综合征的相似之处

Harvengt, J; Lumaka, A; Fasquelle, C; Caberg, J H; Mastouri, M; Janssen, A; Palmeira, L; Bours, V

Homologous recombination repair deficiency (HRD) testing in newly diagnosed advanced-stage epithelial ovarian cancer: A Belgian expert opinion

比利时专家对新诊断的晚期上皮性卵巢癌患者进行同源重组修复缺陷(HRD)检测的意见

Vergote, I; Denys, H; Altintas, S; Kerger, J; Baurain, J-F; Bours, V; Henry, S; Van de Vijver, K; Lambrechts, D; Gennigens, C

The role of germline AIP, MEN1, PRKAR1A, CDKN1B and CDKN2C mutations in causing pituitary adenomas in a large cohort of children, adolescents, and patients with genetic syndromes

在一大群患有遗传综合征的儿童、青少年和患者中,生殖系 AIP、MEN1、PRKAR1A、CDKN1B 和 CDKN2C 突变在导致垂体腺瘤中的作用

Stratakis, C A; Tichomirowa, M A; Boikos, S; Azevedo, M F; Lodish, M; Martari, M; Verma, S; Daly, A F; Raygada, M; Keil, M F; Papademetriou, J; Drori-Herishanu, L; Horvath, A; Tsang, K M; Nesterova, M; Franklin, S; Vanbellinghen, J-F; Bours, V; Salvatori, R; Beckers, A

Increased expression of receptor activator of NF-kappaB ligand (RANKL), its receptor RANK and its decoy receptor osteoprotegerin in the colon of Crohn's disease patients

克罗恩病患者结肠中核因子κB受体激活因子配体(RANKL)、其受体RANK及其诱饵受体骨保护素的表达增加

Franchimont, N; Reenaers, C; Lambert, C; Belaiche, J; Bours, V; Malaise, M; Delvenne, P; Louis, E

Combined suicide and cytokine gene therapy for peritoneal carcinomatosis.

自杀和细胞因子基因疗法联合治疗腹膜癌

Lechanteur C, Delvenne P, Princen F, Lopez M, Fillet G, Gielen J, Merville M P, Bours V